• 1
    Kromer W. Endogenous opioids, the enteric nervous system and gut motility. Dig Dis 1990; 8: 36173.
  • 2
    Ballantyne JC, Mao J. Medical progress: opioid therapy for chronic pain. N Engl J Med 2003; 349: 194353.
  • 3
    Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 64971.
  • 4
    De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 10315.
  • 5
    Bergman L, Djarv L. A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection. Ann Clin Res 1981; 13: 4025.
  • 6
    Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93: 24757.
  • 7
    Rang HP, Dale MM, Ritter JM. Analgesic Drugs. Pharmacology 1999: 579603.
  • 8
    Stefano GB, Goumon Y, Casares F et al. Endogenous morphine. Trends Neurosci 2000; 23: 43642.
  • 9
    Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 1997; 81: 57991.
  • 10
    Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res 1997; 46: 18.
  • 11
    Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993; 16: 118.
  • 12
    Greenwald MK, Stitzer ML, Haberny KA. Human pharmacology of the opioid neuropeptide dynorphin A (1-13). J Pharmacol Exp Ther 1997; 281: 115463.
  • 13
    Mikus G, Trausch B, Rodewald C et al. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 1997; 61: 45966.
  • 14
    Bradford LD, Kirlin WG. Polymorphisms of CYP2D5 in black populations: implications for psychopharmacology. Int J Neuropsychopharmachol 1998; 1: 17385.
  • 15
    Fagerlund TH, Braaten O. No pain relief from codeine...? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001; 45: 1409.
  • 16
    Wilder-Smith CH, Hill L, Osler W, O'Keefe S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999; 44: 110716.
  • 17
    Lacheze C, Coelho AM, Fioramonti J, Bueno L. Influence of trimebutine on inflammation- and stress-induced hyperalgesia to rectal distension in rats. J Pharm Pharmacol 1998; 50: 9218.
  • 18
    Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50, 488H and attenuates morphine withdrawal. EMBO Journal 1998; 17: 88697.
  • 19
    Junien JL, Riviere P. The hypersensitive gut–peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995; 9: 11726.
  • 20
    Coffin B, Bouhassira D, Chollet R et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996; 10: 91926.
  • 21
    Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995; 40: 224449.
  • 22
    Delgado-Aros S, Chial HJ, Camilleri M et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003; 284: G558.
  • 23
    Delgado-Aros S, Chial HJ, Cremonini F et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003; 18: 50714.
  • 24
    Ness TJ. Kappa opioid receptor agonists differentially inhibit two classes of rat spinal neurons excited by colorectal distention. Gastroenterology 1999; 117: 38894.
  • 25
    Pol O, Ferrer I, Puig MM. diarrhoea associated with intestinal inflammation increases the potency of mu and delta opioids on the inhibition of gastrointestinal transit in mice. J Pharmacol Exp Ther 1994; 270: 38691.
  • 26
    Antonijevic I, Mousa SA, Schafer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci 1995; 15: 16572.
  • 27
    Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332: 168590.
  • 28
    Puig MM, Pol O. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice. J Pharmacol Exp Ther 1998; 287: 106875.
  • 29
    Pol O, Palacio JR, Puig MM. The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther 2003; 306: 45562.
  • 30
    Makman MH. Morphine receptors in immunocytes and neurons. Adv Neuroimmunol 1994; 4: 6982.
  • 31
    Philippe D, Dubuquoy L, Groux H et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003; 111: 132938.
  • 32
    Wilder-Smith CH, Hill L, Wilkins J, Denny L. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. Anesthesiology 1999; 91: 63947.
  • 33
    Dowlatshahi K, Evander A, Walther B, Skinner DB. Influence of morphine on the distal oesophagus and the lower oesophageal sphincter – a manometric study. Gut 1985; 26: 8026.
  • 34
    Penagini R, Picone A, Bianchi PA. Effect of morphine and naloxone on motor response of the human esophagus to swallowing and distension. Am J Physiol 1996; 271: G67580.
  • 35
    Penagini R, Bartesaghi B, Zannini P, Negri G, Bianchi PA. Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. Gut 1993; 34: 1620.
  • 36
    Penagini, Bartesaghi B, Negri G, Bianchi PA. Effect of loperamide on lower oesophageal sphincter pressure in idiopathic achalasia. Scand J Gastroenterol 1994; 29: 105760.
  • 37
    Mittal RK, Frank EB, Lange RC, McCallum RW. Effects of morphine and naloxone on esophageal motility and gastric emptying in man. Dig Dis Sci 1986; 31: 93642.
  • 38
    Thorn SE, Wattwil M, Lindberg G, Sawe J. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand 1996; 40: 17786.
  • 39
    Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans.[comment]. Anesthesiology 1997; 87: 76570.
  • 40
    Narducci F, Bassotti G, Granata MT et al. Functional dyspepsia and chronic idiopathic gastric stasis. Role of endogenous opiates. Arch Intern Med 1986; 146: 71620.
  • 41
    Lewis TD. Morphine and gastroduodenal motility. Dig Dis Sci 1999; 44: 217886.
  • 42
    Camilleri M, Malagelada JR, Stanghellini V, Zinsmeister AR, Kao PC, Li CH. Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. Am J Physiol 1986; 251: G14754.
  • 43
    Yukioka H, Rosen M, Evans KT, Leach KG, Hayward MW, Saggu GS. Gastric emptying and small bowel transit times in volunteers after intravenous morphine and nalbuphine. Anaesthesia 1987; 42: 70410.
  • 44
    Yee MK, Evans WD, Facey PE, Hayward MW, Rosen M. Gastric emptying and small bowel transit in male volunteers after i.m. ketorolac and morphine. BJA 1991; 67: 42631.
  • 45
    Stacher G, Steinringer H, Schneider C et al. Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. Dig Dis Sci 1992; 37: 198204.
  • 46
    Borody TJ, Quigley EM, Phillips SF et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology 1985; 89: 56270.
  • 47
    Kachel G, Ruppin H, Hagel J, Barina W, Meinhardt M, Domschke W. Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 1986; 90: 8593.
  • 48
    Kaufman PN, Krevsky B, Malmud LS et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 135156.
  • 49
    Goke M, Ewe K, Donner K, Meyer zum Buschenfelde K.H. Influence of loperamide and loperamide oxide on the anal sphincter. A manometric study. Dis Colon Rectum 1992; 35: 85761.
  • 50
    Musial F, Enck P, Kalveram KT, Erckenbrecht JF. The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol 1992; 15: 32124.
  • 51
    Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982; 27: 80714.
  • 52
    Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997; 32: 3438.
  • 53
    Bharucha AE. Fecal incontinence. Gastroenterology 2003; 124: 167285.
  • 54
    Jivegard L, Thornell E, Bjorck S, Svanvik J. The effects of morphine and enkephaline on gallbladder function in experimental cholecystitis. Inhibition of inflammatory gallbladder secretion. Scand J Gastroenterol 1985; 20: 104956.
  • 55
    Thimister PW, Hopman WP, van Roermund RF et al. Inhibition of pancreaticobiliary secretion by loperamide in humans. Hepatology 1997; 26: 25661.
  • 56
    Hopman WP, Rosenbusch G, Jansen JB, Lamers CB. Effect of increasing oral doses of loperamide on gallbladder motility in man. Br J Clin Pharmacol 1990; 29: 5560.
  • 57
    Thune A, Baker RA, Saccone GT, Owen H, Toouli J. Differing effects of pethidine and morphine on human sphincter of Oddi motility. Br J Surg 1990; 77: 9925.
  • 58
    Radnay PA, Duncalf D, Novakovic M, Lesser ML. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol, and naloxone. Anesth Analg 1984; 63: 4414.
  • 59
    Vieira ZE, Zsigmond EK, Duarate B, Renigers SA, Hirota K. Evaluation of fentanyl and sufentanil on the diameter of the common bile duct by ultrasonography in man: a double blind, placebo controlled study. Int J Clin Pharmacol Ther 1994; 32: 2747.
  • 60
    Feldman M, Walsh JH, Taylor IL. Effect of naloxone and morphine on gastric acid secretion and on serum gastrin and pancreatic polypeptide concentrations in humans. Gastroenterology 1980; 79: 2948.
  • 61
    Feldman M, Moore L, Walsh JH. Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man. Regul Pept 1985; 11: 24550.
  • 62
    Feldman M, Cowley YM. Effect of an opiate antagonist (naloxone) on the gastric acid secretory response to sham feeding, pentagastrin, and histamine in man. Dig Dis Sci 1982; 27: 30810.
  • 63
    Ainsworth MA, Kjeldsen J, Schaffalitzky de Muckadell OB. Morphine inhibits secretion of bicarbonate from the human duodenal mucosa. Possible role of endogenous opioids in the regulation of human duodenal mucosal bicarbonate secretion. Scand J Gastroenterol 1990; 25: 106675.
  • 64
    Turvill J, Farthing M. Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur J Gastroenterol Hepatol 1997; 9: 87780.
  • 65
    Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 1997; 113: 40914.
  • 66
    Talley NJ. Nonulcer dyspepsia: current approaches to diagnosis and management. Am Fam Physician 1993; 47: 140716.
  • 67
    Fraitag B, Homerin M, Hecketsweiler P. Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994; 39: 107277.
  • 68
    Costello DJ, Borison HL. Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther 1977; 203: 22230.
  • 69
    Ariumi H, Saito R, Nago S, Hyakusoku M, Takano Y, Kamiya H. The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett 2000; 286: 12326.
  • 70
    Sussman G, Shurman J, Creed MR et al., International S3AA3013 Study Group. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. Clin Ther 1999; 21: 121627.
  • 71
    Baines M. Nausea and vomiting in the patient with advanced cancer. J Pain Symptom Manag 1988; 3: 815.
  • 72
    Currow DC, Coughlan M, Fardell B, Cooney NJ. Use of ondansetron in palliative medicine. J Pain Symptom Manag 1997; 13: 3027.
  • 73
    Bruera E, Lawlor P, Watanabe S, Turner K, Hanson J. The effects of opioid rotation (OR), dose ratio (DR) on pain control and cognition in patients (P) with cancer pain. Proc Am Soc Clin Oncol 1997; 16: 62a.
  • 74
    Lichter I. Nausea and vomiting in patients with cancer. Hematol Oncol Clin North Am 1996; 10: 20720.
  • 75
    Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 321621.
  • 76
    Hirayama T, Ishii F, Yago K, Ogata H. Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review. Yakugaku Zasshi – J Pharm Soc Jpn 2001; 121: 17985.
  • 77
    Chung F, Lane R, Spraggs C et al., Ondansetron OIE Post-Surgical Study Group. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Eur J Anaesthesiol 1999; 16: 66977.
  • 78
    Williams PI, Smith M. An assessment of prochlorperazine buccal for the prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy. Eur J Anaesthesiol 1999; 16: 63845.
  • 79
    Abrahm JL. Management of pain and spinal cord compression in patients with advanced cancer. ACP-ASIM End-of-life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 1999; 131: 3746.
  • 80
    Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84: 1058.
  • 81
    Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283: 36772.
  • 82
    Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001; 182: 19S26S.
  • 83
    Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996; 59: 46975.
  • 84
    Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 1999; 83: 63135.
  • 85
    Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000; 284: 13834.
  • 86
    Yuan CS, Foss JF, O'Connor M et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000; 67: 398404.
  • 87
    Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001; 182: 27S38S.
  • 88
    Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001; 69: 6671.
  • 89
    Cheskin LJ, Chami TN, Johnson RE, Jaffe JH. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend 1995; 39: 1514.
  • 90
    Rogers R, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989; 11: 1325.
  • 91
    Sandgren JE, McPhee MS, Greenberger NJ. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984; 101: 3314.
  • 92
    Ma H, Tang J, White PF et al. The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification. Anesth Analg 2003; 96: 140912.
  • 93
    Gowing LR, Farrell M, Ali RL White JM. Alpha2-adrenergic agonists in opioid withdrawal.[comment]. Addiction 2002; 97: 4958.
  • 94
    Miedema BW, Johnson JO. Methods for decreasing postoperative gut dysmotility. Lancet Oncol 2003; 4: 36572.
  • 95
    Taguchi A, Sharma N, Saleem RM et al. Selective postoperative inhibition of gastrointestinal opioid receptors.[comment]. N Engl J Med 2001; 345: 93540.
  • 96
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052. [erratum appears in Gastroenterology 1997; 113: 1054.]
  • 97
    Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 23947.
  • 98
    Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 27282.
  • 99
    Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome – a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002; 16: 164954.
  • 100
    Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 3845.
  • 101
    Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PA. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993; 38: 97785.
  • 102
    Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980; 79: 127275.
  • 103
    Farthing MJ. Enkephalinase inhibition: a rational approach to antisecretory therapy for acute diarrhoea. Aliment Pharmacol Ther 1999; 13 (Suppl. 6): 12.
  • 104
    Baumer P, Danquechin Dorval E, Bertrand J, Vetel JM, Schwartz JC, Lecomte JM. Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea.[comment]. Gut 1992; 33: 7538.
  • 105
    Cezard JP, Duhamel JF, Meyer M et al. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology 2001; 120: 799805.
  • 106
    Roge J, Baumer P, Berard H, Schwartz JC, Lecomte JM. The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand J Gastroenterol 1993; 28: 3524.
  • 107
    Vetel JM, Berard H, Fretault N, Lecomte JM. Comparison of racecadotril and loperamide in adults with acute diarrhoea. Aliment Pharmacol Ther 1999; 13 (Suppl. 6): 216.